Takeda Pharmaceutical Company Limited

Ryoma Hara

Yoshihiro Banno

Ryosuke Tokunoh

Takeshi Yamasaki

Hideki Furukawa

Shizuo Kasai

Yoshito Terao

Kousuke Hidaka

Masashi Takahashi

The present invention aims to provide a heterocyclic compound having an IP6K inhibitory action and expected to be useful as a prophylactic or therapeutic agent for&#x2014;diseases such as cardiac failure, diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the SPECIFICATION, or a salt thereof has an IP6K inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for diseases such as cardiac failure, diabetes and the like. 

IP6K inhibitors

Provision of a prophylactic or therapeutic agent for diabetes, which has superior efficacy. A compound represented by the formula: wherein each symbol is as described in the specification, or a salt thereof.

Heterocyclic compound

The present invention provides a heterocyclic compound represented by the following formula (I), which has a glucagon antagonistic action and is useful for the prophylaxis or treatment of diabetes and the like, a compound represented by wherein ring A is an optionally substituted benzene ring and the like; Y is a nitrogen atom and the like; X is &#x2014;O&#x2014; and the like; Ris a hydrogen atom and the like; Rand Rare each independently a hydrogen atom and the like; Ris an optionally substituted hydrocarbon group and the like; Ris a hydrogen atom and the like; and Ris &#x2014;(CH)&#x2014;COOH and the like, or a salt thereof.

Growing community of inventors

Osaka, Japan

Ryoma Hara